ESSA Pharma Inc.
EPIX · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $21 | $21 | $24 | $24 |
| G&A Expenses | $13 | $11 | $13 | $13 |
| SG&A Expenses | $13 | $11 | $13 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $34 | $32 | $37 | $37 |
| Operating Income | -$34 | -$32 | -$35 | -$37 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6 | $6 | $2 | $0 |
| Pre-Tax Income | -$29 | -$27 | -$35 | -$37 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$29 | -$27 | -$35 | -$37 |
| % Margin | – | – | – | – |
| EPS | -0.64 | -0.6 | -0.8 | -0.96 |
| % Growth | -6.7% | 25% | 16.7% | – |
| EPS Diluted | -0.64 | -0.6 | -0.8 | -0.96 |
| Weighted Avg Shares Out | 44 | 44 | 44 | 38 |
| Weighted Avg Shares Out Dil | 44 | 44 | 44 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $6 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$28 | -$26 | -$35 | -$37 |
| % Margin | – | – | – | – |